

#15A/RW
03.18.03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

James M. Lipton

Serial No.: 09/828,272

Filed: April 6, 2001

For: USE OF KPV TRIPEPTIDE FOR
Dermatological Disorders

) Examiner: Lorraine Spector

) Group Art Unit: 1647

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is being deposited this 24th day, February, 2003, with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents and Trademarks, Washington, D.C. 20231.

Deborah Muench
Deborah Muench

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicant responds here to the restriction requirement mailed September 23, 2002.

The Office Action has required the Applicant to elect a "polypeptide with a terminal sequence KPV" from 1) SEQ ID NO: 1, 2) SEQ ID NO: 2, 3) SEQ ID NO: 3 AND 4) SEQ ID NO: 4. (Office Action, p. 2.) Further, the Office Action requires an election "for the anti-inflammatory agent" from a) beclomethasone dipropionate, b) betamethasone, c) cortisone, d) dexamethasone, e) fluconide, f) hydrocortisone, g) methylprednisolone, h) prednisolone, i) prednisone, j) triamcinolone, k) aspirin, l) diflusinal, m) fenoprophen calcium, n) ibuprofen, o) indomethicin, p) meclofenamate sodium, q) naproxen, r) phenylbutazone, s) piroxicam, t) sulindac and u) tolectin sodium.

RECEIVED
MAR 11 2003
TECH CENTER 1600/2900